Somite.ai is a pioneering biotech startup focused on revolutionizing cell-based therapies through the use of advanced artificial intelligence (AI). The company operates in the life sciences and biotechnology market, serving clients such as research institutions, pharmaceutical companies, and healthcare providers. Somite.ai's primary mission is to produce human tissue for cell-based therapies, which can potentially treat a range of conditions including metabolic diseases, muscular dystrophies, and connective tissue syndromes.

The company's innovative approach involves developing a "digital twin" of the embryo. This is essentially a computer model that mimics the development and behavior of a real embryo. By using data from various rich sources like single-cell RNA sequencing (scRNA Seq), single-cell ATAC sequencing (scATAC Seq), and gene expression databases, Somite.ai's digital twin can rapidly identify new protocols for generating different cell types. This helps in discovering new regulators of cell differentiation and optimizing protocols quickly.

Somite.ai is based at the Blavatnik Harvard Life Lab, which provides wet laboratories and coworking spaces for early-stage, high-potential biotech and life science startups affiliated with Harvard University. The company’s founders have a strong academic background, with several publications in prestigious journals such as Nature Biotechnology, Nature Protocols, and Science.

Somite.ai's business model revolves around leveraging its proprietary AI-driven technology to offer solutions for cell-based therapies. The company generates revenue through partnerships, licensing its technology, and providing specialized research services to its clients.

In summary, Somite.ai is at the forefront of using AI to advance cell-based therapies, offering significant potential for treating a variety of diseases and conditions.

Keywords: AI-driven, cell-based therapies, digital twin, biotechnology, life sciences, human tissue, gene expression, Harvard, research, innovation.